Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : ajtj's Post-Lobotomy Market Charts and Thoughts -- Ignore unavailable to you. Want to Upgrade?

To: Jacob Snyder who wrote (45145)	11/30/2021 12:51:59 PM
From: Sun Tzu	Read Replies (3) \| Respond to of 96623

Omicron has the potential to be a great blessing. From what I've read, it cold be 500% more transmittable vs 70% for Delta. This means that pretty soon everyone will have it. Yet if it proves to bring only mild symptoms and be pretty benign, it will effectively become a mass vaccination and we won't have a debate over vaccination. This is the best case scenario.

To: Jacob Snyder who wrote (45145)	11/30/2021 12:54:55 PM
From: ajtj99	Respond to of 96623

Watch 16,163 for support on the NYA. That's the lower 21,2 weekly Bollinger Band and the 50-week SMA: schrts.co The VIX pattern suggests a December rebound to about 17,000 NYA, and then a drop into Jan. opex to about 15,000 NYA. I suspect financials will lead any decline due to tapering, tightening, and earnings.

To: Jacob Snyder who wrote (45145)	12/8/2021 1:37:07 AM
From: Jacob Snyder	1 Recommendation Recommended By ajtj99 Read Replies (2) \| Respond to of 96623

Omicron: A report out of South Africa offered a first glimpse at how vaccinated people might fare against the fast-spreading Omicron variant of the coronavirus. Laboratory experiments found that Omicron seems to dull the power of the Pfizer-BioNTech vaccine, but also hinted that people who have received a booster shot might be better protected. The study, published online on Tuesday, found that antibodies produced by vaccinated people were much less successful at keeping the Omicron variant from infecting cells than other forms of the coronavirus…. Dr. Sigal and his colleagues used antibodies from six people who received the Pfizer vaccine without ever having had Covid-19. They also analyzed antibodies from six other people who had been infected before getting the Pfizer vaccine. The researchers found that the antibodies from all of the volunteers performed worse against Omicron than they did against an earlier version of the coronavirus. Overall, their antibodies’ potency against Omicron dropped dramatically, to about one-fortieth of the level seen when tested with an earlier version of the virus. That low level of antibodies may not protect against breakthrough Omicron infections.… The results could help explain some high-profile superspreading events caused by Omicron. At an office Christmas party in Norway, the virus seems to have infected at least half of 120 vaccinated attendees.… His team found a distinct difference between the two sets of volunteers. The antibodies from the six uninfected vaccinated people were very weak against Omicron. But among the volunteers who had Covid-19 before vaccination, five out of six still produced fairly potent responses. One reason for the difference is that people who are vaccinated after an infection produce higher levels of antibodies than do people who were not infected.… nytimes.com